RACHEL HUCKFELDT
- Type
- Physician · Allopathic & Osteopathic Physicians / Ophthalmology
- Where
- STONEHAM, MA
- NPI
- 1205160173
- Received
- $38,951 in 57 records, 2019 to 2025 ($38,940 general, $11 research)
- As principal investigator
- $1,693,128 of research payments to others in 76 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $8,534 |
| 2024 | General payment | 14 | $13,511 |
| 2023 | General payment | 30 | $12,238 |
| 2022 | General payment | 2 | $200 |
| 2021 | General payment | 1 | $4,320 |
| 2019 | General payment | 6 | $135 |
| 2019 | Research payment | 1 | $11 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | 39 | $25,154 | 2023–2025 |
| SANOFI US SERVICES INC. | 2 | $5,238 | 2023 |
| Regeneron Pharmaceuticals, Inc. | 1 | $4,320 | 2021 |
| Sumitomo Pharma America, Inc. | 4 | $3,770 | 2023–2024 |
| Spark Therapeutics, Inc. | 4 | $298 | 2019–2023 |
| Janssen Global Services, LLC | 1 | $114 | 2022 |
| Inspire Medical Systems, Inc. | 1 | $24 | 2025 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 | 2019 |
| Allergan, Inc. | 1 | $11 | 2019 |
| Travere Therapeutics, Inc. | 3 | $2 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 14 | $32,519 |
| Travel and Lodging | 19 | $5,220 |
| Food and Beverage | 19 | $1,179 |
| Education | 4 | $20 |
| Research payment | 1 | $11 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-06-24 | Janssen Pharmaceuticals, Inc | $370 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-16 | Inspire Medical Systems, Inc. | $24 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-01-30 | Janssen Pharmaceuticals, Inc | $8,140 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-11-25 | Janssen Pharmaceuticals, Inc | $1,110 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-20 | Janssen Pharmaceuticals, Inc | $44 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-20 | Janssen Pharmaceuticals, Inc | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-20 | Janssen Pharmaceuticals, Inc | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-03 | Sumitomo Pharma America, Inc. | $650 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-25 | Janssen Pharmaceuticals, Inc | $716 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-09-25 | Janssen Pharmaceuticals, Inc | $173 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-09-25 | Janssen Pharmaceuticals, Inc | $173 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-07-29 | Janssen Pharmaceuticals, Inc | $1,110 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-29 | Janssen Pharmaceuticals, Inc | $370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-18 | Janssen Pharmaceuticals, Inc | $2,220 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-13 | Sumitomo Pharma America, Inc. | $975 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-07 | Janssen Pharmaceuticals, Inc | $5,180 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-07 | Janssen Pharmaceuticals, Inc | $740 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $123 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $123 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $123 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $123 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $55 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $55 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $55 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-10 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $196 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $196 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $196 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $196 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $140 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $140 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $140 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $140 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-09 | Janssen Pharmaceuticals, Inc | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-21 | Janssen Pharmaceuticals, Inc | $578 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-21 | Janssen Pharmaceuticals, Inc | $578 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-21 | Janssen Pharmaceuticals, Inc | $578 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-21 | Janssen Pharmaceuticals, Inc | $578 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-12 | SANOFI US SERVICES INC. | $5,189 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-12 | SANOFI US SERVICES INC. | $49 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-11 | Sumitomo Pharma America, Inc. | $845 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-04-24 | Spark Therapeutics, Inc. | $97 | Food and Beverage | In-kind items and services | LUXTURNA Biological, OCULAR | 2023 | |
| 2023-03-30 | Sumitomo Pharma America, Inc. | $1,300 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2022-09-30 | Janssen Global Services, LLC | $114 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-03 | Spark Therapeutics, Inc. | $86 | Food and Beverage | In-kind items and services | LUXTURNA Biological, OCULAR | 2022 | |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | $4,320 | Consulting Fee | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | 2021 | |
| 2019-12-16 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | (820) Cholbam Drug, Hepatology | 2019 | |
| 2019-11-06 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | (820) Cholbam Drug, Hepatology | 2019 | |
| 2019-10-13 | Spark Therapeutics, Inc. | $76 | Food and Beverage | In-kind items and services | LUXTURNA Biological, OCULAR | 2019 | |
| 2019-04-30 | Allergan, Inc. | $11 | Research payment | In-kind items and services | Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pedi | 2019 | |
| 2019-04-29 | Spark Therapeutics, Inc. | $37 | Food and Beverage | In-kind items and services | LUXTURNA Biological, OCULAR | 2019 | |
| 2019-03-11 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | (820) Cholbam Drug, Hepatology | 2019 | |
| 2019-02-28 | Regeneron Healthcare Solutions, Inc. | $18 | Education | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-15 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $72,312 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-12-11 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $5,552 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-11-13 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $4,764 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $7,637 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-10-15 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $12,689 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-09-18 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $5,465 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-08-27 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $2,800 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-08-06 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $10,229 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-08-06 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $27,706 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-07-21 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $4,040 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-06-30 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $6,498 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-06-24 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $1,000 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | 2025 |
| 2025-06-12 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $1,216 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-06-02 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $25,366 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-06-02 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $2,241 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-06-02 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $1,549 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-05-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $15,078 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-05-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $8,166 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-05-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $20,978 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-05-28 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $1,950 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | 2025 |
| 2025-05-22 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $8,529 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | 2025 |
| 2025-05-08 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $120 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-05-02 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $7,001 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-04-03 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $27,466 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-04-03 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $1,152 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-03-28 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $3,727 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-02-24 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $24,400 | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $1,901 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $6,106 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $2,479 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $28,469 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $14,035 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-31 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $4,951 | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 |
| 2025-01-30 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $185,164 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | 2025 |
| 2025-01-16 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $35,132 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 |
| 2025-01-16 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $929 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | 2025 |
| 2024-12-05 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $1,795 | MGT-RPGR-022 | 2024 |
| 2024-11-27 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $2,500 | MGT-RPGR-021 | 2024 |
| 2024-11-27 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $5,179 | MGT-RPGR-022 | 2024 |
| 2024-11-27 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $5,100 | MGT-RPGR-021 | 2024 |
| 2024-11-14 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $60 | MGT-RPGR-022 | 2024 |
| 2024-10-04 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $5,576 | MGT-RPGR-021 | 2024 |
| 2024-10-04 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $70,373 | MGT-RPGR-022 | 2024 |
| 2024-08-08 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $2,940 | MGT021 | 2024 |
| 2024-07-18 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $8,419 | MGT021 | 2024 |
| 2024-05-09 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $51,284 | MGT-RPGR-022 | 2024 |
| 2024-04-25 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $629 | MGT021 | 2024 |
| 2024-04-18 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $700 | MGT-RPGR-022 | 2024 |
| 2024-04-04 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $2,942 | MGT-RPGR-022 | 2024 |
| 2024-03-27 | Biogen, Inc. | Massachusetts Eye And Ear Infirmary | $7,664 | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P | 2024 |
| 2024-03-14 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $100,047 | MGT021 | 2024 |
| 2024-03-14 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $3,500 | MGT021 | 2024 |
| 2024-03-14 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $14,813 | MGT021 | 2024 |
| 2024-03-14 | Janssen Research & Development, LLC | Ma Eye and Ear Infrmry Mri | $52,942 | MGT-RPGR-022 | 2024 |
| 2023-10-04 | Janssen Research & Development, LLC | Massachusetts Eye And Ear Infirmary | $474,516 | MGT021 | 2023 |
| 2023-07-06 | Novartis Pharmaceuticals Corporation | Massachusetts Eye & Ear Infirmary | $2,568 | Identifying patients and understanding endpoints in severe visual impairment due to primary outer retinal degeneration | 2023 |
| 2023-03-21 | Biogen, Inc. | Massachusetts Eye And Ear Infirmary | $5,222 | A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Re | 2023 |
| 2023-03-20 | Biogen, Inc. | Massachusetts Eye And Ear Infirmary | $12,491 | An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno- | 2023 |
| 2023-01-09 | Biogen, Inc. | Massachusetts Eye And Ear Infirmary | $7,703 | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P | 2023 |
| 2022-10-13 | Biogen, Inc. | MASSACHUSETTS EYE AND EAR INFIRMARY | $16,055 | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P | 2022 |
| 2022-02-07 | Biogen, Inc. | MASSACHUSETTS EYE AND EAR INFIRMARY | $26,848 | An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno- | 2022 |
| 2021-01-25 | Biogen, Inc. | Massachusetts Eye And Ear Infirmary | $110,238 | An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno- | 2021 |
| 2020-10-22 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $30,911 | A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 | 2020 |
| 2020-08-03 | Biogen, Inc. | MASS EYE & EAR INFIRMARY | $37,216 | An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno- | 2020 |
| 2019-11-30 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-10-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-09-30 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-08-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-08-06 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $34,797 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-07-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-06-30 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-05-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-04-30 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-03-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-02-28 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
| 2019-01-31 | Spark Therapeutics, Inc. | MASS EYE & EAR INFIRMARY | $843 | A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stoneham, MA, county Middlesex County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Stoneham, MA | County Middlesex County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 23,355 | 1,638,365 | 7,044,056 |
| Population, 2020 census P1 | 23,244 | 1,632,002 | 7,029,917 |
| Median age B01002 | 42.2 | 38.9 | 40.0 |
| Under 18 B01001 | 20.8% | 19.5% | 19.4% |
| 65 and over B01001 | 20.4% | 16.3% | 17.9% |
| Households B11001 | 9,749 | 634,215 | 2,785,042 |
| Foreign born B05002 | 11.7% | 23.1% | 18.0% |
| Median household income B19013 | $113,964 | $130,847 | $103,960 |
| Median family income B19113 | $159,885 | $166,449 | $131,675 |
| Per capita income B19301 | $62,866 | $69,556 | $57,897 |
| Poverty rate B17001 | 5.4% | 7.7% | 10.0% |
| Unemployment rate B23025 | 2.2% | 4.4% | 5.2% |
| Civilian labor force B23025 | 13,180 | 946,989 | 3,911,446 |
| Mean commute (minutes) B08013 | 27.8 | 29.9 | 29.1 |
| Bachelor's degree or higher B15003 | 55.9% | 59.5% | 47.3% |
| Housing units B25001 | 10,196 | 664,267 | 3,030,406 |
| Owner-occupied B25003 | 71.0% | 61.3% | 62.5% |
| Renters B25003 | 29.0% | 38.7% | 37.5% |
| Median home value B25077 | $671,900 | $727,800 | $562,100 |
| Median gross rent B25064 | $2,035 | $2,201 | $1,762 |
| White, not Hispanic B03002 | 81.0% | 65.1% | 66.6% |
| Black B03002 | 1.2% | 4.7% | 6.4% |
| Hispanic or Latino B03002 | 4.7% | 9.3% | 13.3% |
| Asian B03002 | 6.8% | 13.6% | 7.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stoneham, MA.
Comments